Abstracts

1119 – Predictors of Daily Oral Preexposure Prophylaxis Uptake Among Eligible Clients in Kenya, 2021-2024

Background Pre-Exposure prophylaxis (PrEP) is a key HIV prevention intervention for high-risk populations. This study assessed demographic, behavioral, and clinical factors associated with PrEP initiation among high-risk populations. Methods A cross-sectional study was conducted among PrEP-eligible clients aged 15 years and above who sought HIV testing and counseling services across 11 Coptic hospital facilities in…

505 – Persistent Low-Level Viremia Among People Living With HIV on TLD in Cameroon: Burden and Predictors

Background Tenofovir+lamivudine+dolutegravir (TLD) has considerably improved the achievement of viral suppression (<1000 copies/ml), with an increased proportion of recipients of care (RoC) in the range of low-level viremia (50-999 copies/ml). Of note, persistent low-level viraemia (pLLV) may indicate suboptimal adherence or emerging drug resistance, which are major causes of treatment failure. This study assessed the…

587 – VRON-0200 Induced Broad and Sustained Anti-HBV Immunity in Patients With Chronic HBV Infection

Background VRON-0200 is an immune-modulator, containing a checkpoint modifier targeting HBV core and pol (but not S) antigens, designed to enhance, broaden, and prolong T cell responses. The current Phase 1b study report evaluates safety, immunogenicity, and HBsAg data from chronically-HBV(CHB) infected patients(pts) that received VRON-0200 alone, and in combination with investigational antivirals, when added to ongoing NUC therapy. Methods CHB pts, NUC-suppressed with HBsAg <500IU/mL(Cohorts 1 and 2;C1/2), or <1,000IU/mL(Cohort 3;C3), were randomized to receive i.m. VRON-0200 prime on D1, w/wo VRON-0200…

1002 – Preference for Long-Acting PrEP Modalities Amongst Persons Who Use Drugs: Vancouver, Canada

Background People who use drugs (PWUD) remain disproportionally affected by HIV in Canada. Despite its proven effectiveness and availability of long-acting options, HIV pre-exposure prophylaxis (PrEP) uptake among PWUD is low. We evaluated PrEP awareness, and modality preferences among PWUD engaged in care in Vancouver’s Downtown Eastside (DTES).  Methods We recruited PWUD age 19 and…

808 – Novel Interactome Network Construction From EV-Derived circRNA in Pregnant Women Living With HIV

Background Despite virologic suppression with ART, pregnant people living with HIV (PLWH) experience a disparate risk of chronic non-AIDS-related morbidities (NAMs) during pregnancy compared to people without HIV infection including preterm labor and small for gestational age. Many studies postulate that NAMs reflect immunological dysfunction from underlying continuous inflammation. Extracellular vesicles (EV) are fundamental to…

857 – Efficacy of Dolutegravir Versus Lopinavir-Based Antiretroviral Treatment Regimens for Infants

Background In 2021, antiretroviral treatment (ART) recommendations for infants were updated from lopinavir/r (LPV/r) to dolutegravir (DTG)-based regimens from 4 weeks of age and 3kg body weight. DTG-based regimens are expected to result in improved treatment efficacy due to increased potency, high resistance barrier, and improved practicality. Methods We conducted two cluster-randomized trials at primary…

870 – Neurocognitive Functioning in Ugandan Youth With HIV: Rural and Urban Differences

Background The influence of sociodemographic (age, sex, education) and HIV factors (viral load, ART regimen) on neurocognition in youth with perinatally acquired HIV (YPHIV) remains unclear due to limited comparison groups. Given large sociodemographic and HIV differences in rural versus urban settings, comparisons between YPHIV from these settings may clarify these effects. In this study,…

1072 – School-Based HIV Prevention for Adolescent Mothers: Population Data From 8 African Countries

Background Adolescent girls in East and Southern Africa (ESA) experience some of the world’s highest HIV incidence, with adolescent mothers representing a particularly vulnerable sub-population. School-based HIV prevention programs can reduce HIV risk by increasing HIV knowledge, promoting safer sexual behaviors, and supporting access to HIV prevention services, including PrEP. However, adolescent mothers, even those…